olodanrigan [Ligand Id: 8374] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL34124 (Ema401, EMA-401, EMA401, Olodanrigan, PD-126055) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| AT2 receptor/Angiotensin II type 2 (AT-2) receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4607] [GtoPdb: 35] [UniProtKB: P50052] | ||||||||
| ChEMBL | Binding affinity to type-2 angiotensin-2 receptor (unknown origin) | B | 7.4 | pKi | 39.5 | nM | Ki | Bioorg Med Chem Lett (2016) 26: 1355-1359 [PMID:26810314] |
| ChEMBL | Inhibition of human AT2 receptor | B | 5 | pIC50 | >10000 | nM | IC50 | J Med Chem (2020) 63: 1978-1995 [PMID:32030982] |
| ChEMBL | Inhibitory activity was evaluated against Angiotensin II receptor, type 2 | B | 9.22 | pIC50 | 0.6 | nM | IC50 | J Med Chem (1996) 39: 625-656 [PMID:8576904] |
| ChEMBL | In vitro binding affinity of compound was measured against angiotensin II (AT2) receptor | B | 9.24 | pIC50 | 0.58 | nM | IC50 | Bioorg Med Chem Lett (1994) 4: 1479-1484 |
| GtoPdb | - | - | 9.3 | pIC50 | - | - | IC50 |
Lancet (2014) 383: 1637-47 [PMID:24507377]; Pain Med (2013) 14: 692-705 [PMID:23489258]; Lancet (2014) 383: 1613-4 [PMID:24507378] |
| AT2 receptor in Rat [GtoPdb: 35] [UniProtKB: P35351] | ||||||||
| GtoPdb | - | - | 7.53 | pIC50 | 29.5 | nM | IC50 | Pain Med (2013) 14: 692-705 [PMID:23489258] |
| AT1 receptor/Type-1 angiotensin II receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL227] [GtoPdb: 34] [UniProtKB: P30556] | ||||||||
| ChEMBL | Inhibition of human AT1 receptor | B | 7.41 | pIC50 | 39 | nM | IC50 | J Med Chem (2020) 63: 1978-1995 [PMID:32030982] |
ChEMBL data shown on this page come from version 33:
Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. (2019) 'ChEMBL: towards direct deposition of bioassay data' Nucleic Acids Res., 47(D1). DOI: 10.1093/nar/gky1075. [EPMCID:30398643]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
